CLAIM AMENDMENTS

Listing of Claims:

Claims 1-23 (canceled)

Claims 24-33 (canceled)

Claim 34 (not entered)

Claim 35 (new): A macrocyclic compound of the formula (1):



(1)

and it's pharmaceutically acceptable salts,

wherein

Fragment A_1 is:

(1-i)



wherein

Y is selected from the group consisting of

H ,  ,  ,  ,

 ,  ,  and  ;

X_1 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_1 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_1 is absent;

when X_1 is -CH-, R_1 is a radical independently selected from the group consisting of



Fragment A_2 is:

(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(2-ii)



wherein

X_2 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_2 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_2 is absent;

when X_2 is -CH-, R_2 is a radical independently selected from the group consisting of



Fragment A_3 is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(3-ii)



wherein

X_3 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_3 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_3 is absent;

when X_3 is -CH-, R_3 is a radical independently selected from the group consisting of



and

;

W_1 to W_{16} are each selected from the group consisting of hydrogen and protecting groups used for orthogonal protection in peptide synthesis;

Fragment T is a radical selected from the group consisting of:



wherein (N) indicates the site of a covalent bond to the nitrogen atom of A_1 of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A_3 of formula (1).

Claim 36 (new): A macrocyclic compound of the formula (1):



(1)

and it's pharmaceutically acceptable salts,

wherein

Fragment A_1 is:

(1-i)



wherein

Y is selected from the group consisting of

H ,  ,  ,  ,

 ,  ,  and  ;

X_1 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_1 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_1 is absent;

when X_1 is -CH-, R_1 is a radical independently selected from the group consisting of



and

Fragment A_2 is:

(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(2-ii)



wherein

X_2 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_2 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_2 is absent;

when X_2 is -CH-, R_2 is a radical independently selected from the group consisting of



Fragment A_3 is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(3-ii)



wherein

X_3 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_3 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_3 is absent;

when X_3 is -CH-, R_3 is a radical independently selected from the group consisting of



W_1 to W_{16} are each selected from the group consisting of hydrogen and a compatible protecting group chosen from:



and

Fragment T is a radical selected from the group consisting of:



wherein (N) indicates the site of a covalent bond to the nitrogen atom of A_1 of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A_3 of formula (1).

Claim 37 (new): A macrocyclic compound of the formula (1):



(1)

and it's pharmaceutically acceptable salts,

wherein

Fragment A_1 is:

(1-i)



wherein

X_1 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_1 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_1 is absent;

when X_1 is -CH-, R_1 is a radical independently selected from the group consisting of:



and

;

Fragment A_2 is:

(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline; or

(2-ii)



wherein

X_2 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_2 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_2 is absent;

when X_2 is -CH-, R_2 is a radical independently selected from the group consisting of



Fragment A_3 is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline; or

(3-ii)



wherein

X_3 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_3 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_3 is absent;

when X_3 is -CH-, R_3 is a radical independently selected from the group consisting of



and

;

Fragment T is a radical selected from the group consisting of:



wherein (N) indicates the site of a covalent bond to the nitrogen atom of A_1 of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A_3 of formula (1).